Ergomed PLC
LSE:ERGO

Watchlist Manager
Ergomed PLC Logo
Ergomed PLC
LSE:ERGO
Watchlist
Price: 1 346 GBX Market Closed
Market Cap: 701.1m GBX
Have any thoughts about
Ergomed PLC?
Write Note

Ergomed PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ergomed PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Ergomed PLC
LSE:ERGO
Total Equity
ÂŁ90.9m
CAGR 3-Years
28%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Total Equity
ÂŁ643.9m
CAGR 3-Years
51%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Total Equity
ÂŁ31.4m
CAGR 3-Years
-8%
CAGR 5-Years
64%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Total Equity
ÂŁ1.5m
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
-18%
C4X Discovery Holdings PLC
LSE:C4XD
Total Equity
ÂŁ24.6m
CAGR 3-Years
9%
CAGR 5-Years
14%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Total Equity
ÂŁ38.5m
CAGR 3-Years
21%
CAGR 5-Years
38%
CAGR 10-Years
39%
No Stocks Found

Ergomed PLC
Glance View

Market Cap
683.5m GBX
Industry
Life Sciences Tools & Services

Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.

ERGO Intrinsic Value
1 143.97 GBX
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Ergomed PLC's Total Equity?
Total Equity
90.9m GBP

Based on the financial report for Jun 30, 2023, Ergomed PLC's Total Equity amounts to 90.9m GBP.

What is Ergomed PLC's Total Equity growth rate?
Total Equity CAGR 5Y
22%

Over the last year, the Total Equity growth was 21%. The average annual Total Equity growth rates for Ergomed PLC have been 28% over the past three years , 22% over the past five years .

Back to Top